NK cell imaging by in vitro and in vivo labelling approaches

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 58, Issue 3, 2014, Pages 276-283

  Galli, F ^a   Histed, S N ^b   Aras, O ^c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cancer; Imaging; Immunotherapy; NK cells; Trafficking

Indexed keywords

FLUORESCENT DYE; NANOPARTICLE; RADIOPHARMACEUTICAL AGENT;

ANTINEOPLASTIC ACTIVITY; CELL LABELING; CELL MIGRATION; FLUORESCENCE IMAGING; HUMAN; IMMUNOTHERAPY; IN VITRO STUDY; NATURAL KILLER CELL; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW; ANIMAL; CELL TRACKING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC USE; IMMUNOLOGY; ISOTOPE LABELING; NEOPLASM; PATHOLOGY; PROCEDURES; SCINTISCANNING; T LYMPHOCYTE;

ANIMALS; CELL TRACKING; HUMANS; ISOTOPE LABELING; KILLER CELLS, NATURAL; NEOPLASMS; RADIOPHARMACEUTICALS; T-LYMPHOCYTES; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 84925223759     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Cheng M, Chen Y, Xiao W, Sun R, Tian Z. NK cell-based immunotherapy for malignant diseases. Cell Mol Immunol 2013;10:230-52.
2. Catchpole B, Gould SM, Kellett-Gregory LM, Dobson JM. Immunosuppressive cytokines in the regional lymph node of a dog suffering from oral malignant melanoma. J Small Anim Pract 2002;43:464-7.
3. Green DR, Bissonnette RP, Glynn JM, Shi Y. Activation-induced apoptosis in lymphoid systems. Semin Immunol 1992;4:379-88.
4. Baxevanis CN, Perez SA, Papamichail M. Cancer immunotherapy. Crit Rev Clin Lab Sci 2009;46:167-89.
5. Kiessling R, Klein E, Wigzell H. "Natural" killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and distribution according to genotype. Eur J Immunol 1975;5:112-7.
6. Sun JC, Lanier LL. NK cell development, homeostasis and function: Parallels with CD81 T cells. Nat Rev Immunol 2011;11:645-57.
7. Kim S, Iizuka K, Aguila HL, Weissman IL, Yokoyama WM. In vivo natural killer cell activities revealed by natural killer cell-deficient mice. Proc Natl Acad Sci USA 2000;97:2731-6.
8. Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: An 11-year follow-up study of a general population. Lancet 2000;356:1795-9.
9. Coca S, Perez-Piqueras J, Martinez D, Colmenarejo A, Saez MA, Vallejo C et al. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer 1997;79:2320-8.
10. Street SE, Cretney E, Smyth MJ. Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood 2001;97:192-7.
11. Smyth MJ, Hayakawa Y, Takeda K, Yagita H. New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer 2002;2:850-61.
12. Bryceson YT, March ME, Ljunggren HG, Long EO. Activation, coactivation, and costimulation of resting human natural killer cells. Immunol Rev 2006;214:73-91.
13. Martin-Fontecha A, Thomsen LL, Brett S, Gerard C, Lipp M, Lanzavecchia A et al. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat Immunol 2004;5:1260-5.
14. Gerosa F, Baldani-Guerra B, Nisii C, Marchesini V, Carra G, Trinchieri G. Reciprocal activating interaction between natural killer cells and dendritic cells. J Exp Med 2002;195:327-33.
15. Costello RT, Sivori S, Marcenara E, Lafage-Pochitaloff M, Moz-ziconacci MJ, Reviron D et al. Defective expression and function of natural killer cell-triggering receptors in patients with acute myeloid leukemia. Blood 2002;99:3661-7.
16. Beckneil B, Caligiuri MA. Interleukin-2, interleukin-15, and their roles in human natural killer cells. Adv Immunol 2005;86:209-39.
17. Rosenberg SA. Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2. J Biol Response Mod 1984;3:501-11.
18. Ma HL, Whitters MJ, Konz RF, Senices M, Young DA, Grusby MJ et al. IL-21 activates both innate and adaptive immunity to generate potent antitumor responses that require perforin but are independent of IFN-gamma. J Immunol 2003;171:608-15.
19. Zamai L, Ponti C, Mirandola P, Gobbi G, Papa S, Galeotti L et al. NK cells and cancer. J Immunol 2007;178:4011-6.
20. Escudier B, Farace F, Angevin E, Charpentier F, Nitenberg G, Triebel F et al. Immunotherapy with interleukin-2 (IL2) and lym-phokine-activated natural killer cells: Improvement of clinical responses in metastatic renal cell carcinoma patients previously treated with IL2. Eur J Cancer A 1994;30A: 1078-83.
21. Ishikawa E, Tsuboi K, Saijo K, Harada H, Takano S, Nose T et al. Autologous natural killer cell therapy for human recurrent malignant glioma. Anticancer Res 2004;24:1861-71.
22. deMagalhaes-Silverman M, Donnenberg A, Lembersky B, Elder E, Lister J, Rybka W et al. Posttransplant adoptive immunotherapy with activated natural killer cells in patients with metastatic breast cancer. J Immunother 2000;23:154-60.
23. Burns LJ, Weisdorf DJ, DeFor TE, Vesole DH, Repka TL, Blazar BR et al. IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: A phase I/II trial. Bone Marrow Transplant 2003;32:177-86.
24. Miller JS, Soignier Y, Panoskaltsis-Mortari A, McNearney SA, Yun GH, Fautsch SK et al. Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. Blood 2005;105:3051-7.
25. Iliopoulou EG, Kountourakis P, Karamouzis MV, Doufexis D, Ar-davanis A, Baxevanis CN et al. A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. Cancer Immunol Immunother 2010;59:1781-1789.
26. Lundqvist A, McCoy JP, Samsel L, Childs R. Reduction of GVHD and enhanced antitumor effects after adoptive infusion of allo-reactive Ly49-mismatched NK cells from MHC-matched donors. Blood 2007;109:3603-6.
27. Zalevsky J, Leung IW, Karki S, Chu SY, Zhukovsky EA, Desjarlais JR et al. The impact of Fc engineering on an anti-CD19 antibody: Increased Fcgamma receptor affinity enhances B-cell clearing in nonhuman primates. Blood 2009;113:3735-43.
28. Kohrt HE, Houot R, Goldstein MJ, Weiskopf K, Alizadeh AA, Brody J et al. CD 137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies. Blood 2011;117:2423-32.
29. Yamane BH, Hank JA, Albertini MR, Sondel PM. The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma. Expert Opin Investig Drugs 2009;18:991-1000.
30. Tonn T, Becker S, Esser R, Schwabe D, Seifried E. Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. J Hematother Stem Cell Res 2001;10:535-44.
31. Nagashima S, Mailliard R, Kashii Y, Reichert TE, Herberman RB, Robbins P et al. Stable transduction of the interleukin-2 gene into human natural killer cell lines and their phenotypic and functional characterization in vitro and in vivo. Blood 1998;91:3850-61.
32. Jha P, Golovko D, Bains S, Hostetter D, Meier R, Wendland MF, Dalmp-Link HE. Monitoring of NK-Cell Immunotherapy using non-invasive Imaging Modalities. Cancer Res 2010;70:6109-13.
33. Kircher MF, Gambhir SS, Grimm J. Noninvasive cell-tracking methods. Nature Reviews Clinical Oncology 2011;8:677-88.
34. Daldrup-Link HE, Meier R, Rudelius M, Piontek G, Piert M, Metz S et al. In vivo tracking of genetically engineered, anti-HER2/ neu directed natural killer cells to HER2/neu positive mammary tumors with magnetic resonance imaging. Eur Radiol 2005;15:4-13.
35. Sheu AY, Zhang Z, Omary RA, Larson AC. MRI-monitored tran-scatheter intra-arterial delivery of SPIO-labeled natural killer cells to hepatocellular carcinoma: Preclinical studies in a rodent model. Invest Radiol 2013;48:492-9.
36. Tavri SI, Jha P, Meier R, Henning TD, Müller T, Hostetter D et al. Optical imaging of cellular immunotherapy against prostate cancer. Mol Imaging 2009;8:15-26.
37. Edinger M, Cao YA, Verneris MR, Bachmann MH, Contag CH, Negrin RS. Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. Blood 2003;101;640-8.
38. Meiler B, Frohn C, Brand JM, Lauer I, Schelper LF, von Hof K et al. Monitoring of a new approach of immunotherapy with allogenic niIn-labelled NK cells in patients with renal cell carcinoma. Eur J Nucl Med Mol Imaging 2004;31:403-7.
39. Matera L, Gaietto A, Bello M, Baiocco C, Chiappino I, Castellano G et al. In vivo migration of labeled autologous natural killer cells to liver metastases in patients with colon carcinoma. J Transi Med 2006;4:49.
40. Schäfer EI, Dummer R, Eilles C, Börner W, Martin R, Rendi J et al. Imaging pattern of radiolabelled lymphokine-activated killer cells in patients with metastatic malignant melanoma. Eur J Nucl Med 1991;18:106-10.
41. Melder RJ, Brownell AL, Shoup TM, Brownell GL, Jain RK. Imaging of activated natural killer cells in mice by positron emission tomography: Preferential uptake in tumors. Cancer Res 1993;53:5867-71.
42. Meier R, Piert M, Piontek G, Rudelius M, Oostendorp RA, Se-nekowitsch-Schmidtke R et al. Tracking of [18F]FDG-labeled natural killer cells to HER2/neu-positive tumors. Nucl Med Bio 2008;35:579-88.
43. Galli F, Rapisarda A, Stabile H, Malviya G, Bonanno E, Gismondi A et al. Synthesis of ^Tc-anti-CDSo monoclonal antibody for molecular imaging of NK cells: In vitro and in vivo studies. Eur J Nucl Med Mol Imaging 2013;40(Suppl 2):S89-S567